Exciting Data and Trials in Progress from ASCO 2024

Author(s):

Pedro Barata, MD, MSc,Martin H. Voss, MD

Elizabeth Wulff-Burchfield, MD, facilitates a conversation about several clinical trials, such as STELLAR-001 and KEYNOTE-426, which investigate various treatment approaches for renal cell carcinoma (RCC).

EP: 1.Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC

EP: 2.Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER

EP: 3.Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC

EP: 4.Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials

Now Viewing

EP: 5.Exciting Data and Trials in Progress from ASCO 2024

EP: 6.Ongoing RCC Clinical Trials that may Impact Practice

EP: 7.Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes

EP: 8.Dr Voss Application of Updated KEYNOTE-564 Data

EP: 9.Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition

EP: 10.World Health Organization (WHO) Classification Updates for Papillary RCC

EP: 11.Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC

EP: 12.The Role of Chemotherapy in nccRCC Treatment

EP: 13.Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape

EP: 14.Final Thoughts/Looking Forward

Please briefly discuss recent findings from ongoing trials and novel treatment strategies.
1. STELLAR-001 single-agent zanzalintinib biomarker analysis (Pal et al, ASCO 2024)
2. KEYNOTE-426 Phase 3 pembro + axitinib biomarker analysis (Rini et al., ASCO 2024 Abstract 4505)
3. Phase 3 trial len + pembro + belzutifan/quavonlima (Choueiri, ASCO GU 2022: Abstract TPS399)